Phase 3 Development of Resmetirom: a Liver-Directed Thyroid Hormone Receptor (THR)-Beta Agonist for the Treatment of Patients with NASH and Significant Liver FibrosisImpacting NASH: Focus on Liver and Cardiovascular Benefits
(as presented at EASL 2021)
The contribution of metabolic co-morbidities and hepatic thyroid hormone dysregulation to the pathophysiology of NASHVlad Ratziu, MD, PhD
The utilization of biomarkers for the identification of NASH patients and as predictors of treatment response in the clinical settingJörn Schattenberg, MD
Resmetirom as a treatment for NASH: Updates from the MAESTRO Phase 3 clinical trialsStephen A. Harrison, MD, FACP, FAASLD
Wayne Eskridge tells his personal journey as a patient with NASH and how it led him to develop the Fatty Liver Foundation.
Wayne Eskridge gives his advice to patients dealing with NASH, and NASH expert, Dr Scott Friedman, talks about what support clinicians should provide.
Epidemiology of NASH—CV and Liver Related OutcomesZobair M. Younossi
MD, MPH, FACP, FACG, AGAF, FAASLD
Real-life Treatment of NASH: Imaging in NASH. MRI-PDFF to Predict Benefit in Patients with NASH: Focus on ResmetiromRohit Loomba